Kewaunee Scientific (KEQU) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
13 Mar, 2026Executive summary
Completed acquisition of Nu Aire, Inc. on November 1, 2024, expanding product offerings and market reach, and contributing to diversification and offsetting construction market weakness.
Sales for the quarter ended January 31, 2026, increased to $69.4M from $67.2M year-over-year, a 3.3% rise; nine-month sales rose to $210.6M from $163.3M.
International sales grew 21.4% for the quarter and 27.0% for the nine months, driven by higher billings, especially in India.
Domestic sales for the quarter were flat or down 2.0% year-over-year to $51.0M, but up 29.6% for the nine months due to the Nu Aire acquisition.
Order backlog decreased to $183.2M from $221.6M year-over-year, indicating a slowdown in new orders.
Financial highlights
Gross profit margin for the quarter was 26.7% (down from 27.4%); gross profit was $18.5M; nine-month margin was 28.1% (up from 27.4%).
Operating expenses for the quarter were $16.0M (23.0% of sales), flat year-over-year; nine-month operating expenses rose to $47.7M (22.6% of sales) from $35.6M (21.8%).
Net earnings for the quarter were $692K ($0.23 per diluted share), down from $1.35M ($0.45); nine-month net earnings were $6.23M ($2.09), down from $6.56M ($2.20).
EBITDA for the quarter was $3.8M, nearly flat year-over-year; adjusted EBITDA was $3.98M, reflecting integration costs for the Nu Aire acquisition.
Operating cash flow for nine months was $13.2M, up from $5.4M year-over-year; cash on hand at quarter-end was $10.3M, down from $17.2M at the start of the fiscal year.
Outlook and guidance
Demand visibility remains limited due to the company’s subcontractor role and project-based business; management expects continued softness in construction-related business due to seasonal and macroeconomic factors.
Third quarter results reflect typical seasonal volatility and were further impacted by geopolitical and economic uncertainty.
Growth and diversification strategy validated by Nu Aire’s contribution, offsetting softness in construction-related business.
Investments in corporate infrastructure and readiness for SEC accelerated reporting are expected to support future inorganic growth.
Latest events from Kewaunee Scientific
- Sales surged 46.8% to $70.1M, but net earnings dropped 18.7% amid integration costs.KEQU
Q2 202612 Dec 2025 - Q1 FY2026 sales and earnings surged, fueled by the Nu Aire acquisition and a strong backlog.KEQU
Q1 202610 Dec 2025 - Annual meeting to vote on directors, auditor, executive pay, and governance policies.KEQU
Proxy Filing2 Dec 2025 - Annual meeting to vote on director, auditor, and executive pay, with a focus on governance and performance.KEQU
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, auditors, and executive pay, with board support for all.KEQU
Proxy Filing2 Dec 2025 - Annual meeting to vote on director, auditor, and executive pay, all board-recommended.KEQU
Proxy Filing2 Dec 2025 - Adjusted earnings and sales surged, fueled by Nu Aire integration and strong domestic growth.KEQU
Q4 202526 Jun 2025 - Gross margin and net earnings rose as Nu Aire was acquired and backlog reached a record high.KEQU
Q2 202513 Jun 2025 - Backlog and quoting activity remain strong despite a slight year-over-year earnings decline.KEQU
Q1 202513 Jun 2025